Short Interest in Kamada Ltd. (NASDAQ:KMDA) Drops By 48.6%

Key Points

• Kamada Ltd. experienced a significant 48.6% decline in short interest in July, with a total of 47,300 shares sold short as of July 31st.
• The company reported $0.13 earnings per share for the quarter, exceeding the consensus estimate of $0.09, although revenue fell short at $44.75 million against an expected $158.59 million.
• Analysts maintain a positive outlook, with Benchmark and Wall Street Zen issuing "buy" and "strong-buy" ratings, respectively, and price targets as high as $15.00 per share.

Kamada Ltd. (NASDAQ:KMDA - Get Free Report) saw a significant drop in short interest during the month of July. As of July 31st, there was short interest totaling 47,300 shares, adropof48.6% from the July 15th total of 92,000 shares. Approximately0.2% of the shares of the company are sold short. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is presently 0.7 days. Based on an average daily trading volume, of 70,300 shares, the days-to-cover ratio is presently 0.7 days. Approximately0.2% of the shares of the company are sold short.

Analyst Ratings Changes

KMDA has been the topic of several analyst reports. Benchmark reiterated a "buy" rating and set a $15.00 price target on shares of Kamada in a research note on Thursday, May 15th. Wall Street Zen upgraded Kamada from a "buy" rating to a "strong-buy" rating in a research report on Wednesday, May 21st. Finally, Sidoti raised Kamada to a "hold" rating in a report on Thursday, May 8th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $13.00.

Kamada Stock Performance

Shares of NASDAQ KMDA traded up $0.13 during midday trading on Friday, reaching $7.18. The stock had a trading volume of 21,642 shares, compared to its average volume of 50,648. The company has a market capitalization of $412.92 million, a price-to-earnings ratio of 21.12, a price-to-earnings-growth ratio of 0.75 and a beta of 0.93. Kamada has a 12-month low of $5.17 and a 12-month high of $9.15. The stock has a 50-day moving average of $7.48 and a 200-day moving average of $7.07.

Kamada (NASDAQ:KMDA - Get Free Report) last issued its earnings results on Wednesday, August 13th. The biotechnology company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.09 by $0.04. Kamada had a net margin of 11.22% and a return on equity of 7.41%. The company had revenue of $44.75 million during the quarter, compared to the consensus estimate of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, analysts forecast that Kamada will post 0.23 EPS for the current fiscal year.

Hedge Funds Weigh In On Kamada

A number of hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. bought a new stake in Kamada during the 4th quarter valued at approximately $67,000. Trexquant Investment LP purchased a new stake in Kamada during the 1st quarter valued at approximately $82,000. NewEdge Advisors LLC grew its holdings in Kamada by 54.2% during the 4th quarter. NewEdge Advisors LLC now owns 23,496 shares of the biotechnology company's stock valued at $143,000 after buying an additional 8,260 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Kamada by 5.6% during the fourth quarter. Geode Capital Management LLC now owns 29,289 shares of the biotechnology company's stock valued at $178,000 after buying an additional 1,549 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Kamada in the first quarter worth $206,000. Institutional investors own 20.38% of the company's stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.